Selective ETA and dual ETA/ETB endothelin receptor antagonists (ERAs) [24] have been utilized in clinical settings to alleviate blood pressure and proteinuria in CKD patients and treat PAH. This evidence concerns the gene EDNRA and chronic kidney disease.